Felicia J. Fooh-Tjien
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
Journal: Annals of surgical oncology
Published: July 12, 2025
Correction: Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
Journal: Annals of surgical oncology
Published: January 30, 2025
Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head and Neck Melanoma Using the Merlin Assay (CP-GEP).
Journal: Annals of surgical oncology
Published: July 12, 2024
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 31, 2022
Clinicopathologic models predicting non-sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
Journal: Journal of surgical oncology
Published: August 02, 2021
Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Journal: International journal of dermatology
Published: December 22, 2020
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Journal: JCO precision oncology
Published: May 15, 2020
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026